Experiences with
Tyrosine745 public posts
Want to take advantage of all our features? Just log in!
or
Zanubrutinib-Gazyva Shows Promise for CLL/SLL
June 25, 2019
Zanubrutinib (BGB-3111) is an investigational small molecule inhibitor of Bruton’s tyrosine kinase (BTK). Gazyva is a monoclonal antibody designed to bind to CD20, a protein found on the surface of certain types of B cells, including malignant CLL or SLL cells.
Efficacy of venetoclax monotherapy in patients with relapsed CLL in the post‐BCR inhibitor setting: a UK wide analysis
At ≥2 lines, 60% received a Bruton Tyrosine Kinase inhibitor (BTKi) and no prior phosphoinositide 3‐kinase inhibitor (Pi3Ki), 25% received a Pi3Ki and no prior BTKi, and 10% received both.
Patients discontinued B cell receptor inhibitor (BCRi) because of toxicity in 44% and progression in 54%.